Abstract

Background Natural killer (NK) cells are critical in viral control and NK cells that respond to HIV-1 peptides have been described. However, it is unclear how NK cells recognize HIV-1 antigen. We investigated NK cell responses to HIV-1 peptides during early and chronic HIV-1 clade B infection. Methods NK cells responding to HIV-1 peptides were assessed by multiparameter flow cytometry using whole blood from 74 individuals with treated or untreated early or chronic HIV-1 infection. In addition, 15 HIV uninfected individuals were also studied. Results No NK cell responses to HIV-1 peptides were detected in HIV-1 uninfected individuals. The HIV-1 NK cell specific responses to peptide were less frequent during the first year of infection but were of high magnitude and frequent in individuals with controlled or progressive infection (22% vs 79%; P<0.00001). The activation of NK cells to peptide pools required the presence of plasma IgG and the responding NK cells had a low CD16 expression and high CD57 expression. Furthermore, plasma derived from HIV-1 infected individuals was sufficient to trigger a response to HIV-1 Env peptide pool by NK cells from healthy donors suggesting the role of antibodies in mediating this activity. Conclusion NK cell responses to specific antigens can be induced in HIV-1 infection. Large cohorts are needed to assess the consequences of these NK cells against HIV-1 control or protection from infection.

Highlights

  • Natural killer (NK) cells are critical in viral control and NK cells that respond to HIV-1 peptides have been described

  • We investigated NK cell responses to HIV-1 peptides during early and chronic HIV-1 clade B infection

  • No NK cell responses to HIV-1 peptides were detected in HIV-1 uninfected individuals

Read more

Summary

Introduction

Natural killer (NK) cells are critical in viral control and NK cells that respond to HIV-1 peptides have been described. Frequent and strong antibody-mediated NK cell activation to HIV-1 Env in individuals with chronic HIV-1 infection C Thobakgale1*, L Fadda2, K Lane2, I Toth2, F Pereyra2, S Bazner2, T Ndung’u1, BD Walker2, E Rosenberg2, G Alter2, M Carrington3, T Allen2, M Altfeld2 From AIDS Vaccine 2012 Boston, MA, USA.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.